Terazosin
 | |
| Names | |
|---|---|
| Trade names | Hytrin, Zayasel, others |
| Other names | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone |
| |
| Clinical data | |
| Defined daily dose | 5 mg[1] |
| External links | |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693046 |
| Legal | |
| Legal status |
|
| Pharmacokinetics | |
| Protein binding | 90-94% |
| Elimination half-life | 12 hours |
| Chemical and physical data | |
| Formula | C19H25N5O4 |
| Molar mass | 387.440 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure.[2] For high blood pressure, it is a less preferred option.[2] It is taken by mouth.[2]
Common side effects include dizziness, headache, tiredness, swelling, nausea, and low blood pressure with standing.[2] Severe side effects may include priapism and low blood pressure.[2] Prostate cancer should be ruled out before starting treatment.[2] It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.[2]
Terazosin was patented in 1975 and came into medical use in 1985.[3] It is available as a generic medication.[4] A month supply in the United Kingdom costs the NHS less than £2 as of 2019.[4] In the United States the wholesale cost of this amount is about US$4.50.[5] In 2017, it was the 194th most commonly prescribed medication in the United States, with more than two million prescriptions.[6][7]
Medical use
Dosage
The defined daily dose is 5 mg by mouth.[1]
It is available in 1 mg, 2 mg, 5 mg or 10 mg doses.[8]
Synthesis
Reaction of piperazine with 2-furoyl chloride followed by catalytic hydrogenation of the furan ring leads to 2. This, when heated in the presence of 2-chloro-6,7-dimethoxyquinazolin-4-amine (1) undergoes direct alkylation to terazosin (3).
References
- ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 7 September 2020.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Terazosin Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.
- ↑ 4.0 4.1 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 768. ISBN 9780857113382.
- ↑ "NADAC". Centers for Medicare and Medicaid Services. 27 February 2019.
- ↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ↑ "Terazosin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- ↑ "Terazosin Hydrochloride Capsule". DailyMed. National Library of Medicine, National Institutes of Health.
- ↑ US 4026894, Winn M, Kyncl J, Dunnigan DA, Jones PH, issued 31 May 1977, assigned to Abbott
External links
| Identifiers: |
|---|
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugboxes which contain changes to watched fields
- Alpha blockers
- Tetrahydrofurans
- Piperazines
- Quinazolines
- Phenol ethers
- Carboxamides